



Press Release

July 19, 2021

## Save the date for the Scandion Oncology Capital Markets Day on September 8, 2021

### Scandion Oncology A/S invites investors, analysts, and media to a virtual Capital Markets Day on September 8, 2021.

During the day, Scandion Oncology's executive management will provide a corporate strategy update, a deep dive into the clinical strategy and the business opportunities to pursue our goal of becoming The Cancer Drug Resistance Company.

Specific details will be provided in August, but please **save the date** or **register now** at [https://www.lyyti.fi/reg/Capital Markets Day Scandion Oncology 7500](https://www.lyyti.fi/reg/Capital_Markets_Day_Scandion_Oncology_7500)

The presentation will be held in English.

#### For further information regarding Scandion Oncology A/S, please contact:

Bo Rode Hansen, President & CEO

Phone: +45 3810 2017

E-mail: [info@scandiononcology.com](mailto:info@scandiononcology.com)

Website: [www.scandiononcology.com](http://www.scandiononcology.com)

The information was provided by the contact person above for publication on July 19, 2021.

#### About Scandion Oncology A/S

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. **Ticker: SCOL.**

For more information, please visit [www.scandiononcology.com](http://www.scandiononcology.com) and sign up for news releases.

For frequent updates, please also follow us on [LinkedIn](#) and [Twitter](#).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.